Podcasts about prognostication

Le Dr Sarah Benghanem, Réanimatrice dans le service de Médecine Intensive Réanimation de l'hôpital de Cochin à Paris, nous parle de la neuropronostication après un arrêt cardiorespiratoire autour de 3 questions : Qu'est-ce que la neuropronostication ? Pourquoi est-elle essentielle après un arrêt cardiorespiratoire ? Chez quel malade et dans -quels délais doit-elle être réalisée ? Quels sont les outils à notre disposition en 2024 et quelle est la place de chacun d'eux ? Quelles sont les nouvelles pistes pour améliorer la neuropronostication dans les années à venir ? Aucun conflit n'est déclaré. Références : Nolan et al, European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care, Intensive Care Medicine and Resuscitation 2021, DOI: 10.1007/s00134-021-06368-4 Sandroni et al, Prediction of poor neurological outcome in comatose survivors of cardiac arrest: a systematic review, Intensive Care Medicine 2020, DOI: 10.1007/s00134-020-06198-w Sandroni et al, Prediction of good neurological outcome in comatose survivors of cardiac arrest: a systematic review, Intensive Care Medicine 2022, DOI: 10.1007/s00134-022-06618-z Benghanem et al, Prognostication after cardiac arrest: how EEG and evoked potentials may improve the challenge, Annals of intensive care 2022, DOI: 10.1186/s13613-022-01083-9

Today:Conservative commentator and never-Trumper Bill Kristol of The Bulwark discusses the American right, and the complicated relationship conservatives have with Donald Trump.And, if you're still unsure whether to drop the MCAS as a graduation requirement, or legalize psychedelics, Evan Horowitz of Tufts Center for State Policy Analysis – ballot question explainer extraordinaire – gives one last rundown ahead of election day.

In this pre-election episode, the guys talk about the upcoming election on Tuesday, November 5th. Dave gives his electoral college and popular vote predictions. G.K. has a thought about the inauguration which the guys decided to share after the election in the next episode. Be sure to visit our website at www.miningthemedia.com and please share with your friends, relatives, associates, and neighbors. 

Send us a textThis week on the Get More Smarter Podcast, Gabe-ish Evans is running one of the most confusing campaigns for Congress we've ever seen; will it matter in the closest contest in Colorado? Then, check your mailboxes because it's time to vote! Ballots are either in the mail (or if you already voted, on the way back); instead of filling them out, we're just going to predict what's going to happen in our first 2024 edition of of "Prognostication." Donald Trump is a confused old man sweatin' to the oldies as Kamala Harris waltzes into the Lion's Den and shows Fox News why she's ready to be the 47th president of the United States. But first...get in losers, we're going losing. She can't win a State Senate Seat in North Carolina, but it absolutely won't be from lack of effort. Kate Barr joins us on the podcast today to discuss her losing campaign, gerrymandering, democracy, and why she's going through all the effort just to lose. 

In this politically charged episode of God Talk, we dive into the complexities of the upcoming 2024 presidential election, just three weeks away. As Christians, what is our duty in the face of two flawed candidates? We explore the long-standing campaign dynamics, the surprising nomination of Kamala Harris, and the implications for voters. Join us as we discuss why the election is less about the candidates themselves and more about the policies they represent. We delve into the culture war that is, at its core, a 'God war,' challenging the values and future of America. From immigration and free speech to crime and inflation, we examine the critical issues at stake. Discover the momentum behind the betting markets, which predict a significant lead for Trump, and hear a bold prediction for the electoral outcome. Will this election cycle bring unexpected results? Tune in for a thought-provoking analysis on the intersection of faith, politics, and the future of our nation.

The team are back to talk about postseason baseball. They discuss the wonder and the farce that was the Mets v Braves Monday double header and then talk through who is gonna all the ropunds of the play offs.Who do they they think are going to make it to the World Series, listen in to find out.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on machine-learning for phenotyping and prognostication of myocardial infarction and injury in suspected acute coronary syndrome.

Featuring a slide presentation and related discussion from Dr Priyanka Sharma, including the following topics: Biomarker Assays in the Identification and Prognostication of Patients with Breast Cancer (0:00) Utility of Circulating Tumor DNA in the Prognostication of Localized Breast Cancer (24:28) Treatment of HR-Positive, HER2-Negative Advanced Breast Cancer with a PI3K Mutation (29:46) Utility of Subsequent CDK4/6 Inhibitor After Disease Progression on Initial Therapy (34:57) Treatment of HER2-Low or HER2-Ultralow Metastatic Breast Cancer (40:59) Updated Data and Novel Strategies Involving Trastuzumab Deruxtecan for the Treatment of Advanced Breast Cancer (49:42) Oral Selective Estrogen Receptor Degraders for the Treatment of ER-Positive, HER2-Positive Breast Cancer (51:55) Novel Strategies Involving Antibody-Drug Conjugates and Immunotherapy for Triple-Negative Breast Cancer (58:12) CME information and select publications

Hour 2 - It is a perfect time to welcome Chiefs Radio Network Executive Producer Dan Israel back to Sports Daily.

Send us a Text Message.In this episode of DigiPath Digest, broadcasting from Poland,  we delve into advances in digital pathology, including AI applications in bone marrow evaluation, classification of hematology cells, and the use of synthetic images for data augmentation. Additionally, we review a survey on pathologists' perceptions of ChatGPT and consider the feasibility of GANs for enhancing medical image analysis.00:00 Welcome and Troubleshooting from Poland00:21 Live Stream Challenges and Conference Details02:21 Digital Pathology Podcast Introduction02:51 Technical Difficulties and Audience Interaction06:18 Exploring Digital Pathology Papers06:43 Advances in Bone Marrow Evaluation09:03 AI in Hematology and Pathology12:28 Colorectal Cancer Prognostication19:34 Pan-Cancer Xenograft Repository25:16 ChatGPT and Pathology Survey30:55 Synthetic Image Generation in Pathology36:35 Upcoming Conferences and Courses42:27 Closing Remarks and Future PlansTHE ABSTRACTS WE COVERED TODAY

Developments in school bus manufacturing, updates on the Clean School Bus Program, and concerns on Montgomery (Md.) County Public Schools electrification plans. What will the future of electric school buses look like? “I love every part of it.” Garage Star Teno Gustavson, director of vehicle and facilities maintenance for Suffolk Transportation Service in New York, discusses his 35-year career in the industry, fleet electrification (which the contractor pioneered in the state), infrastructure trends, inventory management, and more. Read more about operations.

Patients with severe acute brain injury often lack the capacity to make their own medical decisions, leaving surrogate decision makers responsible for life-or-death choices. Patient-centered approaches and scientific methodologies can guide clinicians' prognostications. In this episode, Teshamae Monteith, MD, FAAN, speaks with Susanne Muehlschlegel, MD, MPH, FNCS, FCCM, FAAN, author of the article “Prognostication in Neurocritical Care,” in the Continuum® June 2024 Neurocritical Care issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Muehlschlegel is a professor (PAR) in the departments of neurology, anesthesiology/critical care medicine and neurosurgery, division of neurosciences critical care at Johns Hopkins University School of Medicine in Baltimore, Maryland. Additional Resources Read the article: Prognostication in Neurocritical Care Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Guest: @SMuehlschMD Transcript Full transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic- based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, a companion podcast to the Journal. Continuum Audio features conversations with the guest editors and authors of Continuum, who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article by visiting the link in the show notes. Subscribers also have access to exclusive audio content not featured on the podcast. As an ad-free journal entirely supported by subscriptions, if you're not already a subscriber, we encourage you to become one. For more information on subscribing, please visit the link in the show notes. AAN members, stay tuned after the episode to hear how you can get CME for listening. Dr Monteith: This is Dr Tesha Monteith, Associate Editor of Continuum Audio. Today, I'm interviewing doctor Susanne Muehlschlegel about her article on prognostication in neurocritical care, which is part of the June 2024 Continuum issue on neurocritical care. Well, Susanne, thank you so much for coming on the podcast, and thank you for writing that beautiful article. Dr Muehlschlegel: Thank you so much for having me. Excited to be here. Dr Monteith: Why don't we start with you just introducing yourself? Dr Muehlschlegel: Yeah, sure. My name is Susanne Muehlschlegel. I'm a neurointensivist at Johns Hopkins in Baltimore, Maryland. I have been a neurointensivist for about eighteen years or so. I worked previously at the University of Massachusetts and recently arrived here at Hopkins. Dr Monteith: Cool. So, what were you thinking about - What information did you want to convey - when you set out to write your article? Dr Muehlschlegel: Yeah. So, the article about neuroprognostication is really near and dear to my heart and my research focus, and I'm very passionate about that part. And as neurologist and neurointensivist, prognostication, you know, might be considered the bread and butter of what we're asked to do by families and other services, but as the article states, is that we don't usually do a great job (or physicians sometimes believe they do). But when you actually do research and look at data, it's probably not as good as we think, and there's a lot of room for improvement. And, so, the reason for this article really was to shine the light at the fact that I think we need to really make neuroprognostication a science, just like we make prediction models a science - and, so, that is the main topic of my research, as well as the article. Dr Monteith: So, we know about your interest in research in this area, but what got you into critical care to begin with? Dr Muehlschlegel: Yeah. It's, pretty much, a story of always being drawn to what's exciting and what others may want to avoid. So, in medical school, people were afraid of neurology and learning all the anatomy, and I just loved that and loved interacting with these patients. And then, in neurology residency, I was drawn to not just treating the brain and the spinal cord, but also the entire patient (so the lung and the heart and the interaction of all the organs). And then, naturally, I'm a little bit of an impatient person, and so I like the environment of the ICU of rapid change and always having to be on my toes. And so that's what drew me into neurocritical care. It was a very new field when I was training, and so, I was probably, you know, one of the, maybe, first- or second-generation neurointensivists. Dr Monteith: And it sounds like you're maybe okay with uncertainty and a lot of variability? Dr Muehlschlegel: Well, you know, neuroprognostication - I think everyone has to acknowledge that we cannot take away uncertainty, right? So, folks who pretend that they know for sure what's going to happen - I think the only time we can say that is in a patient who's braindead. But everyone else, we really don't know for sure, and all we can do is do the best to our ability to give a rough outlook - but we need to acknowledge uncertainty, that's for sure. Dr Monteith: So, can you just give us a few of the biggest causes of variability when it comes to withdrawing life-sustaining therapies in patients with severe acute brain injuries? Dr Muehlschlegel: So, that's the focus of quite some research. And, of course, there are many epidemiological factors, patient severity of disease, and, you know, how fast someone might arrive to the hospital, ethnic, racial, social demographic factors (and there's research on that), but when you adjust and control for all of those factors, variability remains. And so, what I've observed in my practice and what I also describe in the article is that maybe it's the way physicians describe prognostication or communicate with families, meaning there is potentially the chance for physician bias - that may also drive prognostication. And I can tell you from my own experience, what really drove me into this area is anecdotal experience that probably we've all had of other physicians kind of nihilistically prognosticating, thinking, you know, "This is going to be bad no matter what”, and not even wanting to try to provide aggressive care to patients. So, I think these what we call “self-fulfilling prophecies” we need to be very aware of. So, I think some of the variability may be driven by other factors other than family, patient, or health system factors. Dr Monteith: And you outline that really nicely in the article, so thank you for that. Why don't you just give us an example of a challenging case that maybe you're still thinking about today, that maybe happened years ago, that helps us understand what you go through? Dr Muehlschlegel: Yeah, I'll rephrase the case. I still have, you know, very vivid memories about this, but I tell my residents about this case. When I was a fellow, there was a young patient in his early forties, a father of several children, a young family man who had a big right MCA stroke and really was progressing to the point that it was clear that he needed a hemicraniectomy or he was going to die. Discussed this with my attending, who said I should consult neurosurgery. At the time, the neurosurgical service had a transition to practice service for these emergencies - and so, these were fairly young, chief residents or early-year attendings. And the person came in, went into the patient's room, and I didn't even know about it, and came out and then just said, “Family decided for CMO”. I was very surprised and shocked and was trying to understand how this happened, and this provider, all he said was, “Well, it's all how you put it to the family. I told him that he probably shouldn't be a vegetable. They didn't want him to be a vegetable, and so this was the only option.” And, so, I was very shocked, and the patient did progress to die within a few days. And, so, that was a dire example of how biased prognostication can drive families to maybe an unnecessary outcome. Dr Monteith: And what's CMO? Dr Muehlschlegel: I'm sorry. Comfort measures only - so, essentially, a withdrawal of life-sustaining therapies. Dr Monteith: Yeah. That is a good example of that and how our bias can inform families and maybe not with the exact amount of data to support that, as you outlined so nicely in your article. Dr Muehlschlegel: And I do want to emphasize, I don't want to generalize that all providers are like that, but it is an example that really still sticks in the back of my mind, and I think, you know, we need to shine a light at how we do this and how we do it right or wrong. Dr Monteith: And wouldn't it be nice to just have more objective measures (right?) to guide us? So why don't we talk about existing tools that are used to help guide neuroprognostication? Dr Muehlschlegel: Yeah, so I think, in general, we can break down prognostication to two pieces (and I outline that in the article as well). So, one is, kind of, a derivation of prognostication in the head of a physician or, you know, clinician – and what may go into that is how the patient presented, examination, radiology or other diagnostics, biomarkers, you name it. But, then the second part of it (that also is really important) is how we put it to the family, right? Because we can influence families in a way that we may not even be aware of, and I think we all have unconscious biases, and how we talk to families is really important and may drive what happens to the patient as well. So, I always say there's two pieces to that – so, first of all, how we come up with a prognosis, and then how we disclose that to the family. Dr Monteith: So how can we better handle uncertainty? Dr Muehlschlegel: So, we actually did some research on that and we asked stakeholders, "How do you want physicians to handle uncertainty?”. People are aware that no physician can be certain (again, other than in the case of brain death), and so families are very aware of that. And there's quite some data out there to suggest that if physicians have very absolute statements - you know, want to close the door by saying something very absolute - is that the optimistic bias in families goes up. So, the mistrust in what the physician is saying, coming up with their own (you know, “This is a fighter, and he or she is going to do better than what you're saying”) - and, so, I think, you know, there's no true answer to what's the absolute right way to do it, but some have suggested to maybe fully acknowledge that there is uncertainty. That's actually what families want you to do, based on some qualitative research we've done – is to say, “I do not have a crystal ball. There will be uncertainty”, but then to potentially go into a best/ worst-case scenario. But again, there, all we can do is give a best gross estimate and guess. And so, the work is not really clear at this point. There's research ongoing as to what should be the best way of doing it, but currently, that's what is suggested. Dr Monteith: And in your article, you spoke about some pretty innovative approaches, such as modeling, to help guide shared decision-making. And, so, you know, how reliable is that? Dr Muehlschlegel: That's a good point, right? So, that is up to statisticians or those who are inventing these new models. So, you know, in the old days we used logistic regression, maybe linear regression. Now, there are fancy machine-learning modeling and other Bayesian models that people use, and they certainly have some advantages that I outlined in the article. Bayesian models, for example, may use serial data as it comes in throughout the patient's hospital course - and that's kind of how we do it in real life. But, I think what's really important before we apply models is that we know that there's always outliers, and we don't know if this one patient might be the outlier, and that we need to validate these models, and most importantly, look at calibration. So, I talk in the article about how, you know, all models always report the what's called “area under the receiver-operating curve (the AUC)”, which is discrimination. But, what's actually more important for a model to be applied to a patient at the bedside is calibration, meaning how well does it actually predict a potential outcome. And, you know, there's a lot of research into that, that only maybe half of the papers that report on a new model actually report calibration - so, I think it's really important to pay attention to that (has the model been validated and calibrated before we actually use these models?). I think prediction models have definitely a important role. But, then again, as the article says, we also have to think about how we then apply that to the patient and how we do it in individual patients. Dr Monteith: And then, of course, there's some variability between institutions. Dr Muehlschlegel: That's for sure. You know, there's these systematic approaches or system-based cultures in certain institutions. And then, of course, you know, there's still this model of learning from a role model or a mentor or an attending - meaning you look at how this person does it and then you may adapt it to your own practice. I think we need to critically examine whether we need to continue with that kind of apprenticeship model of learning how to neuroprognosticate, or whether we need to have other educational ways of doing that. So, especially in the field of palliative care, there's a lot of education now around communication - and I think med students get that exposure, and residents may get that exposure, too - but I think we need to practice it and study it systematically, whether having a standardized approach to do this leads to more patient-congruent decisions. Dr Monteith: And, you know, we do have a lot of trainees, residents, and fellows that listen in. So, what are some key messages that you want to make sure gets conveyed? Dr Muehlschlegel: Key messages is that, I think, we need to move away from looking at a patient the first one or two weeks and then concluding that we will know what will happen to this patient in six months or a year or further down the line. I think there's not a lot of longitudinal studies out there now that show that patients actually probably do better than expected if they're allowed to live. And what I mean by that is many studies allow early withdrawal of life-sustaining therapies within the first three days or maybe two weeks - but if we actually allow these patients to live, people wake up more than we thought, people may do better than we thought. So, referring to the article, I discuss in detail some twelve-month data from the TRACK-TBI study or very interesting results from South Korea where withdrawal of life-sustaining therapies is forbidden by law. And, so, you can actually do a true natural-history study of what happens with these patients if you allow them to live. And, surprisingly, a lot of people that, you know, within the first two weeks were still comatose actually ended up waking up. And, I think it's really important to look at those studies and to continue to conduct those studies so that we know better what might happen. I always shudder a little bit when I hear, “We need an MRI in the first few days or first week for neuroprognostication”. And then I always question, “Well, what is it really going to tell you about that patient who clearly isn't brain dead and still has certain, you know, exam findings?” and “Shouldn't we just give those patients time?”. I think some of those were a bit too quick to provide poor prognostication if we really don't know. Dr Monteith: And, so, I want to know how did you get into research? You know, it can be competitive to get funding, grant funding - so, tell us about that in terms of, you know, your day-to-day, what's it like? And then, also, what makes you most excited about research happening in this area? Dr Muehlschlegel: Yeah, I mean, there's a lot of research happening in that area. I think there's a huge focus on biomarkers and models and all sorts of new diagnostic tools to predict outcome, big push over decades now to do large longitudinal epidemiological studies - and all of those are very, very important, you know. I just mentioned as an example, the TRACK-TBI study is one of many other examples. I'm also excited about doing research in the second part of neuroprognostication that I mentioned - the communication and disclosure part - and the potential of bias as we speak to families. So, I get very excited about that part. It's not easy to get funding, but I think what's important is to focus on the potential impact. And, of course, then you try to convince funders that this is important research that has to be done in addition to funding model development and large epidemiological studies. What my day-to-day looks like? Well, you know, we have several ongoing projects (I won't get into details on that), but to get involved would probably be the best time as a trainee - so, I have medical students working with us, residents and fellows (although their time can be limited). And then to continue to just be curious and ask questions. Dr Monteith: And what do you find most exciting about the work that you do? Just, kind of, overall? Dr Muehlschlegel: I mean, without a doubt, the potential impact, right? So, changing the field a little bit. I'm not claiming that my research is doing that - I hope it might. But, most importantly, it's the potential impact on families and patients. I think our goal is not to have less withdrawal of care (although, sometimes, I just think we need to give people more time), but I think it's important to focus and ask about what patients might want, and then really focus families onto that. I think that can be difficult, because patients don't always tell families what they would want or families want something different than what they know the patient might want - and so, we spend quite some time on that when we speak to families. And then, I also talk about the disability paradox. So, you know, at one point, the family might say, “Well, he would not want to live if he can't walk”, but then, patients, as they learn to live with this new normal, may actually later say, “Well, it's not as bad as I expected it to be, and I'm actually very happy to be alive, even if I'm not able to walk”. And so, that's something that others are doing research on, and that's also important to consider. Dr Monteith: Yeah, that's cool. Thinking about outside of the ICU, right? Dr Muehlschlegel: For sure. Yes. Dr Monteith: Great. Thank you so much for being on our podcast. I know that our listeners are going to really enjoy reading your article and all the thought that you put into that. Dr Muehlschlegel: Thank you so much for having me.   Dr Monteith: Again, today, we've been interviewing Dr Susanne Muehlschlegel whose article on prognostication in neurocritical care appears in the most recent issue of Continuum on neurocritical care. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is doctor Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, please consider subscribing to the journal. There's a link in the episode notes. We'd also appreciate you following the podcast and rating or reviewing it. AAN members, go to the link in the episode notes and complete the evaluation to get CME for this episode. Thank you for listening to Continuum Audio.

Braden Gellenthein, Steve, and George are back with the Third Quadrennial Olympic Prognostications as Paris 2024 launches the first arrows this week.

Prognostication is not an exact science. So, when patients ask the inevitable question, “How much time do I have, doc?” How can we answer? In this episode, Dr. John Mulder and Dr. Jason Beckrow reflect on the challenge of prognostication and how they leverage their years of experience to try and provide patients with the gift of time.

The art and science of forecasting litigation outcomes just got a lot more sciencey. Years of immersion in complex business disputes is bound to shine a light on problems begging for solutions. In this case, our guest observed the laborious and ineffective slog that is trying to forecast how long a case will take, how much it might cost, which jurisdiction will treat it with kindness, or how a judge might rule on a motion for summary judgment. These are some of the critical questions our guest set out to address through the use of technology and assessment of massive data sets. He is Dan Rabinowitz, Co-Founder and CEO of  Pre/Dicta, a six-year-old company that provides litigation prediction and forecasting services.  Before Pre/Dicta, Dan was an attorney in Sidley Austin LLP's Supreme Court and Appellate Group and the firm's Mass Tort Litigation Group. Later, he served as trial attorney in the U.S. Department of Justice, general counsel to a data science company, and associate general counsel, chief privacy officer, and  director of fraud analytics for WellPoint Military Care.Listen to what Dan has to say about how the power of technology is going to make predicting litigation as commonplace as predicting the weather. He also shares insights into a study Pre/Dicta conducted that tested assumptions about judges based on their political affiliations.  *******This podcast is the audio companion to the Journal of Emerging Issues in Litigation. The Journal is a collaborative project between HB Litigation Conferences and the vLex Fastcase legal research family, which includes Full Court Press, Law Street Media, and Docket Alarm.If you have comments, ideas, or wish to participate, please drop me a note at Editor@LitigationConferences.com.Tom HagyLitigation Enthusiast andHost of the Emerging Litigation PodcastHome Page

Deep-Learning Models for the Prognostication and Localization of Premature Ventricular Contractions Using a 12-Lead Electrocardiogram Guest: Guru G. Kowlgi, M.B.B.S. Host: Anthony H. Kashou, M.D.    In this episode, learners will understand what premature ventricular contractions are. They will learn to differentiate benign rom malignant PVCs, and understand which patients are at risk for PVC-cardiomyopathy. Furthermore, they will gain knowledge about the traditional and novel tools for risk-stratifying patients with PVCs, and how we manage these patients.   Topics Discussed What are PVCs and what are their clinical implications? When should we be concerned about a patient with PVCs? What are some of the tools we have to detect and localize high risk PVCs? How does AI help in this regard? What are the available treatment modalities for managing PVCs? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

In this week's episode, Dr Nick Morris is joined by Dr Susanne Muehlschlegel, Dr Katja Wartenberg, and Dr Krishna Rajajee to discuss the NCS' Neuroprognostication Guidelines, including guidelines development, clinical prediction models, and the best language for family meetings.

When it comes to the global economy, many have tried and failed in predicting its course. With a great many factors at play - some predictable, some not - we must first understand the relationships between its moving pieces. In this episode, Rod puts on his economist hat and we dive into five critical issues facing the economy in 2024: inflation, interest rates, growth of the economy, election year, and geopolitical tensions.   Money Insights is a strategic planning firm that is founded on the principle that "off-the-shelf" products and solutions often do not meet the needs of high-income earners. The Money Insights team works to collaboratively design customized financial solutions that will leave a lasting impact on each of their unique clients.   Visit Money Insights and take the Investor Quiz at https://moneyinsightsgroup.com ! Listen to the Money Insights podcast on Spotify, Apple Podcasts, or at https://moneyinsightsgroup.com/podcast

Examine how ChatGPT's predictive capabilities outdo traditional financial analysts in forecasting stock market movements and trends accurately. Get on the AI Box Waitlist: https://AIBox.ai/ Join our ChatGPT Community: https://www.facebook.com/groups/739308654562189/ Follow me on Twitter: https://twitter.com/jaeden_ai

James and Al skewer so-called family values Republicans after recent scandals and welcome polling experts Fred Yang and Jim Gerstein.  They dive into the weak numbers being put up by the Biden campaign, analyzing what's bringing them down, the composition of the electorate, the role of 3rd party candidates, the messaging challenges ahead, and how to take the lead.  They cover the effects of inflation, the crisis at the border, the lack of enthusiasm among young and minority voters, the Israel-Hamas war, and whether Dobbs has given Democrats a silver bullet.  Plus with the year kicking off, James and Al tackle the latest in college sports as long time fans. Email your questions to James and Al at politicswarroom@gmail.com or tweet them to @politicon.  Make sure to include your city, we love to hear where you're from! Check James Carville's new videos: James Carville Explains… Moms For Liberty #TrumpStinks James Carville Explains… Why Mike Johnson is a P.O.S. James Carville Explains… everything about Mike Johnson James Carville on the trail of Lauren Boebert Get More From This Week's Guests: Jim Gerstein  GBAO Strategies  Fred Yang: Twitter | Hart Research  Please Support Our Sponsors: Henson Shaving: Go to hensonshaving.com/pwr and enter PWR at checkout to get 100 free blades with your purchase. (Note: you must add both the 100-blade pack and the razor for the discount to apply.) Zbiotics: Get back into action with Zbiotics with 15% off your first order of the perfect solution to a night out when you go to zbiotics.com/pwr and use code: PWR

Jonathan Elmer, MD, MS is an associate professor of emergency medicine, critical care medicine, and neurology at the University of Pittsburgh Medical Center. He received his Batchelor's degree in biochemistry from Swarthmore and his medical degree from Mount Sinai School of Medicine. He completed his residency in emergency medicine at ...

The Holidays are nearing their end, so lets not continue a trend. Instead of a top 10 again and again, we will look into the future and pretend to be wise men. The gaming is light, and movies alright, lets spend a short while, and talk with artistic style. OK, no more rhyming, we have some light news for you all this week, Sony and War Thunder have some heat, Insomniac stands tall and GTA Hacker gets sentenced. Meanwhile Peaches is out of season at the Oscars, Scream 7 loses its sails, and Aquaman swims slowly to a win. Plus my most anticipated in 2024.

In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Adrian Mosquera, Clinical Hematologist at the University Hospital of Santiago de Compostela, about his research team's novel machine learning model that incorporates patient characteristics and histological subtype into risk prognostication for mantle cell lymphoma (MCL). In addition, Dr. Mosquera shares more of his research utilizing artificial intelligence for designing more risk-tailored therapeutic approaches and facilitate personalized medicine in hematologic malignancies.

Wherein I thoroughly enjoy a full slate of top-level rugby, particularly in the URC, which I grow increasingly convinced is the best league of any sport in this crazy world. The article about Fabien Galthie was here: https://www.rte.ie/sport/rugby-world-cup/2023/1108/1415469-france-will-carry-world-cup-scars-forever-galthie/ The primary website for all the WXV action that I have woefully inadequately covered is here: https://www.wxvrugby.com/ The blurb about the Eagles' win over Brazil was here: https://eagles.rugby/news/usa-mens-eagles-make-a-statement-in-dominant-win-over-brazil-20231111 If you're enjoying listening, you can always buy me a beverage through the link below, or you can sign up through Anchor to become a monthly supporter! If you still haven't left a review, I'd really appreciate it if you could take that bit of time, it's really more helpful than I can say. In the meantime, thanks as always for your support! https://www.buymeacoffee.com/ScrumOfTheEarth https://anchor.fm/thescrumoftheearth Sound bites commonly used in this show are from the fantastic show, “Still Game,” available on Netflix, I highly recommend it. Thanks, cheers and be well! --- Support this podcast: https://podcasters.spotify.com/pod/show/thescrumoftheearth/support

In this episode, the gang chats through the preview and recent preorders and asks a key question: has 40K lost some of its panache when it comes to new model releases, particularly when compared to Age of Sigmar? We also chat through our thoughts on GW's new website and the controversy around its update. Jump in, and happy hobbying! We are proudly sponsored by Versatile Terrain! You can find their awesome products at versatileterrain.co.uk Conclave Crew: Adam/ADR Wargaming - Instagram: @adrwargaming Rich G - Instagram: @gwatkingaming Rich S - Instagram: @rezzaprime Josh - Instagram: @warhipster Jamie - Instagram: @sanguinary_punk The Conclave Socials: Instagram: www.instagram.com/theconclave40k Facebook: www.facebook.com/theconclave40k Twitter: @TheConclave40K --- Send in a voice message: https://podcasters.spotify.com/pod/show/theconclave40k/message

Dr. Neha Dangayach talks Drs. Susanne Muehlschlegel and Adeline Goss about characterizing the prognostic language clinicians use in critical neurologic illness. Read the related article in Neurology. Visit NPUb.org/Podcast for associated article links.

This week Matthew (Shadow Marvel) and Justin sit down with Brian Watson to talk about Everwinter and give our predictions about the upcoming AMG Ministravaganza. And immediately see our track record wrecked. Sign up for Everwinter by going to their Wicked Dicey webpage. You can also get all the information from Everwinter by joining their Discord. Join the discussion with your feelings and thoughts on the game by joining our Discord⁠! If you would like to further support the channel go here to find out more: https://www.patreon.com/ThegamersguildIf you have any questions send them here: thegamerguild24@gmail.comOr find us on Facebook here. If you are in the US, shop at: https://gamechefs.org to help support the guild and use code: GamersGuild to save an additional 15% on your order!   If you are in the UK, shop at: http://www.tritex-games.co.uk/ to help support the guild and use code: TRITEXGGCP5 to save an additional 5% on any of your MCP purchases! You can also find Tritex Games on Facebook here: https://www.facebook.com/tritexgames/and on Twitter here: https://twitter.com/TritexGamesLtd

This episode features Caitlin Spooner (Marie Curie Palliative Care Research Department, University College London, London, UK).  What is already known about the topic? - Currently, there is no gold standard for evaluating how different methods of prognosticating in advanced cancer impact on patient care. - Prognostic models are principally evaluated by their statistical performance, determining their discrimination and calibration. However, before any prognostic model can be recommended for use in clinical practice, it is necessary to demonstrate whether or not it has a beneficial impact on patient care. - There is a lack of consensus among stakeholders about how to assess the impact of prognostication in advanced cancer, with prognostic studies varying in the outcomes they select.  What this paper adds? - We identified a wide variety of outcomes and measures used in published studies, which makes inter-study comparability problematic. - Our findings highlight the widespread effect that prognostication in advanced cancer has on patients and informal caregivers. - The lived experiences of patients and informal caregivers regarding prognostication in advanced cancer are not always represented in the outcomes quantitative prognostic studies measure.  Implications for practice, theory, or policy - Further research is needed to identify and prioritise outcomes to measure the impact of prognostication in advanced cancer. - Patients' and informal caregivers' experiences and perspectives should always be incorporated when evaluating the impact of prognostication. - Outcome selection in prognostication studies needs to be more consistent and standardised.  Full paper available from:    https://journals.sagepub.com/doi/full/10.1177/02692163231191148  If you would like to record a podcast about your published (or accepted) Palliative Medicine paper, please contact Dr Amara Nwosu: a.nwosu@lancaster.ac.uk

Wondering if you should get a biopsy? Wanting to understand more about the biopsy of your eye? Join A Cure in Sight and back again, the wonderful Dr. Basil K Williams to discuss Prognostication of the Eye – A special episode selected and sponsored by Castle Biosciences. Learn about the classes of eye tumors, what newer research tells us, and where research is headed. ANNOUNCEMENTS: 5K SITES ARE OPEN FOR REGISTRATION NEAR YOU! Start your team and bring your community to get involved!  September 23, Denver, CO https://runsignup.com/Race/CO/Denver/LookinForACureDenver November 18, Los Angeles CA https://runsignup.com/Race/CA/SantaMonica/LookinForACureLosAngeles November 19, Phoenix, AZ https://runsignup.com/Race/AZ/Scottsdale/LookinforaCure5k December 9, Dallas FTW TX https://runsignup.com/Race/TX/FortWorth/LookinForACureFortWorth December 10, Houston, TX https://runsignup.com/Race/TX/Houston/LookinForACureHouston January 20, 2024 Orlando FL https://runsignup.com/Race/FL/Orlando/LookinForACureTampa January 21, 2024, Miami FL https://runsignup.com/Race/FL/Miami/LookinForACureMiami Head to our site to register for a 5K Lookin' for a Cure near you for the remainder of the year!! www.lookinforacure.org  REGISTER TODAY for the Eye Believe Survivorship Seminar happening in Seattle, WA, Sept 8-9, 2023! Subscribe to the newsletter to stay in the know Newsletter link Email contact@acureinsight.org for questions regarding any upcoming events! ********* Be sure to follow us on Facebook, Twitter, Linked In, or  Instagram @acureinsight, for more stories, tips, research news, and ideas to help you navigate this journey with OM! *A Cure in Sight is a 501c3 organization. All donations made can help fund our podcast to educate patients, fund research, aid patients, and more! Donate $10 $15 $20 today to help A Cure in Sight in their quest to find a cure. Contribute via  PAYPAL OR VENMO or reach out directly to contact@acureinsight.org 

Full article: https://www.ajronline.org/doi/abs/10.2214/AJR.23.29609  Hong Linda Li, MD discusses a new AJR article that details how preoperative MRI-based staging can predict biochemical recurrence of prostate cancer after radical prostatectomy as effectively as post-surgical pathologic staging.

When in the mindset of reading the horoscope, we access in a different state of mind. This state allows us to be in touch with a peripheral field of information.  So what exactly is it we're doing when working with astrology and how does it produce such accurate results?  To quote today's guest, Richard Swatton: “you can't predict technique – you can have techniques of prediction but the prediction arrives in the moment” During this episode Richard and I discuss the other-worldly aspects of astrology, delving into the eighth house depths of a subject already coaxing us deeper into the realms of the subconscious. Richard has lead many different paths in this lifetime: Musician, Occultist, Psychotherapist, Astrologer and Tutor at the London School of Astrology. He is also the Author of Symbol to Substance and his new book The Horary Process: A Magical Approach to an Ancient Art, is due to be published at the end of 2023.  You'll understand why I feel so blessed to have learned at the LSA when you hear how fascinating, intelligent and inspiring Richard is. Without wanting to sound like Hannibal Lecter, what I wouldn't give for a slice of that brain... LOL.   How do you feel viewing astrology as a divinatory art?   TIMESTAMPS 00:01:26 About Richard | 00:05:52 Symbol to substance book | 00:07:31 The real Psychological astrology | 00:09:03 interconnectedness: music of the spheres | 00:15:05 the basis of prognostication | 00:16:46 coming of age with Saturn | 00:22:19 the unfathomable mystery of it | 00:24:47 Astrology & Mythology plus Persephone | 00:28:10 Pluto and my motherhood/maitrescence journey | 00:34:48 Transits triggering individualtion | 00:36:59 Prediction of particulars & divination | 00:40:10 The Ogres of ancient Rome | 00:40:53 a symbolic state of mind | 00:47:33 Going deep with Sun signs alone | 00:50:26 The Appearance of symbol in substance | 00:53:04 Ptolemy's Centiloquium | 00:55:05 “a shock of white hair” | 00:58:26 What is inspiration? The 9 Muses/Urania | 01:04:09 Richards new book: the Horary Process | 01:07:28 Astrology as a training and symbol system | 01:11:53 Aligning ourselves with a greater will | 01:13:58 Horary is inclusive | 01:17:18 Astrology appears IRL | 01:21:03 Richards Books/readings with Richard   CHART Neptune appears: 6/7/21, Newhaven, UK, 09:00 GMT   LINKS Watch this episode: https://youtu.be/dNqDsIMrrxM The Astrology Squad https://astrologysquad.com/ From Symbol to Substance: Training the Astrological Intuition by Richard Swatton https://www.amazon.co.uk/Symbol-Substance-Training-Astrological-Intuition/dp/1516984447 The Horary Process: A Magical Approach to an Ancient Art contact: info@flareUK.com Saturn by Liz Greene https://www.goodreads.com/book/show/603038.Saturn Books by Dane Rudhyar https://www.goodreads.com/author/list/417055.Dane_Rudhyar Books by Howard Sasportas https://www.goodreads.com/author/list/309821.Howard_Sasportas Books by Stephen Arroyo https://www.goodreads.com/search?q=stephen+arroyo&qid=JCD35IIqxU Ptolemy's Centiloquium https://www.skyscript.co.uk/centiloquium1.html Tetrobiblos by Claudius Ptolemy https://en.wikisource.org/wiki/Tetrabiblos Ptolemy https://www.astro.com/astrowiki/en/Ptolemy Christian Astrology by William Lilley https://archive.org/details/ChristianAstrologyByWilliamLilly/mode/2up Christian Astrology retyped by Deb Houlding at Skyscript https://www.skyscript.co.uk/CA/CA_DH.pdf   To book a reading with Richard contact me and I will pass your details to Richard: stelliumastro@gmail.com  

This week, please join author Joe-Elie Salem and Guest Editor Allan Jaffe as they discuss the article "Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis." For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20230807.753501

Timmy is back from camp, while Andrew is on his way to the annual family retreat in Arkansas. We are both in the thick of balancing family time with summer ministry obligations while trying to find and recruit some new staff members. Both Lakeview and Safety Harbor held unique holiday weekend worship services that were more popular than anyone was expecting. --- Send in a voice message: https://podcasters.spotify.com/pod/show/morningafterministryshow/message

When will Messiah come? We are all curious to know the answer. What if we can find evidence or proof in Scripture to know when the redemption will happen? Isn't that a tantalizing notion? In this podcast we survey the prohibition, futility, and peril of Messianic prognostication. – – – – – – – – […]

When will Messiah come? We are all curious to know the answer. What if we can find evidence or proof in Scripture to know when the redemption will happen? Isn't that a tantalizing notion? In this podcast we survey the prohibition, futility, and peril of Messianic prognostication.– – – – – – – – – – – – – – – – – – – – – –DONATE: Please consider supporting the podcasts by making a donation to help fund our Jewish outreach and educational efforts at https://www.torchweb.org/support.php. Thank you!– – – – – – – – – – – – – – – – – – – – – –Email me with questions, comments, and feedback: rabbiwolbe@gmail.com– – – – – – – – – – – – – – – – – – – – – –SUBSCRIBE to my Newsletterrabbiwolbe.com/newsletter– – – – – – – – – – – – – – – – – – – – – –SUBSCRIBE to Rabbi Yaakov Wolbe's PodcastsThe Parsha PodcastThe Jewish History PodcastThe Mitzvah Podcast This Jewish LifeThe Ethics PodcastTORAH 101 ★ Support this podcast ★

Sports prognostication at its finest

Tony Kornheiser and Michael Wilbon come together to discuss the biggest topics in sports including how the Lakers should feel after barely beating a Timberwolves team missing two starters, if they praise the Hawks or blame the Heat for last night's Play-In outcome, and if they have the Bruins or the field to win the Stanley Cup. Learn more about your ad choices. Visit megaphone.fm/adchoices

Who's gonna win what?

It might be early in the 2024 election season, but that doesn't mean there aren't significant events, candidates, polling and topics to tune into. Nathan Gonzales, Roll Call's elections analyst and the publisher of Inside Elections, joins the podcast to discuss why it's so important to pay attention to what's going on now.  Learn more about your ad choices. Visit megaphone.fm/adchoices

It might be early in the 2024 election season, but that doesn't mean there aren't significant events, candidates, polling and topics to tune into. Nathan Gonzales, Roll Call's elections analyst and the publisher of Inside Elections, joins the podcast to discuss why it's so important to pay attention to what's going on now.  Learn more about your ad choices. Visit megaphone.fm/adchoices

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021.Originally released: April 25, 2019 For patients who survive cardiopulmonary arrest but do not wake up, neurologists are called to the bedside to prognosticate. And the question of “How much will this patient recover?” is not unlike “What is the benefit of aggressive therapy to await possible recovery?” In that way, you might consider neurologists to be the actuaries of hospital medicine. In this week's program, we review the clinical and diagnostic data that neurologists incorporate into their model for outcome prediction following anoxic brain injury. Produced by James E Siegler. Music courtesy of Swelling, Soft and Furious, Rafael Archangel, Lovira, and Dark Room. Sound effects by Mike Koenig and Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES Booth CM, Boone RH, Tomlinson G, Detsky AS. Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrest. JAMA 2004;291(7):870-9. PMID 390099PMID: 14970067 Callaway CW, Donnino MW, Fink EL, et al. Part 8: Post-Cardiac Arrest Care: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015;132(18 Suppl 2):S465-82. Erratum in: Circulation 2017;136(10 ):e197. PMID 390099PMID: 26472996 Jorgensen EO, Holm S. The natural course of neurological recovery following cardiopulmonary resuscitation. Resuscitation 1998;36(2):111-22. PMID 9571727 Nielsen N, Wetterslev J, Cronberg T, et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med 2013;369(23):2197-206. PMID 24237006 Sandroni C, D'Arrigo S. Neurologic prognostication: neurologic examination and current guidelines. Semin Neurol 2017;37(1):40-7. PMID 28147417 Sandroni C, Cariou A, Cavallaro F, et al. Prognostication in comatose survivors of cardiac arrest: an advisory statement from the European Resuscitation Council and the European Society of Intensive Care Medicine. Resuscitation 2014;85(12):1779-89. PMID 25438253 Seder DB. Management of comatose survivors of cardiac arrest. Continuum (Minneap Minn) 2018;24(6):1732-52. PMID 30516603 Seder DB, Sunde K, Rubertsson S, et al. Neurologic outcomes and postresuscitation care of patients with myoclonus following cardiac arrest. Crit Care Med 2015;43(5):965-72. PMID 25654176 Young GB. Clinical practice. Neurologic prognosis after cardiac arrest. N Engl J Med 2009;361(6):605-11. PMID 19657124We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

In this podcast, JNIS Editor-in-Chief, Dr. Felipe C. Albuquerque, speaks with Dr. Kyle Fargen(1) about the recently published study "Mechanical thrombectomy decision making and prognostication: Stroke treatment Assessments prior to Thrombectomy In Neurointervention (SATIN) study" - https://jnis.bmj.com/content/early/2023/01/05/jnis-2022-019741.long Please subscribe to the JNIS Podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest episodes. Also, please consider leaving us a review or a comment on the JNIS Podcast iTunes page: https://podcasts.apple.com/gb/podcast/jnis-podcast/id942473767 Thank you for listening! This episode was edited by Brian O'Toole. (1) Neurological Surgery and Radiology, Wake Forest University, Winston-Salem, North Carolina, USA

Librarian, author, blogger, podcaster -- our guest Betsy Bird wears a lot of hats. She is not only a bona fide children's book expert but also has a great knack for predicting ALA Awards! As the awards are being given out at the end of this month, Betsy's going to take us behind the scenes and talk about the mysterious process of how the awards are even chosen, and what books MIGHT take home some hardware this year! (Will we be right? WHO KNOWS!  But it will be fun to find out!) She also answers some listener questions about library etiquette, book banning, what she'd like to see more of in the picture book space, and more.   Check out the show notes for more information, links to all the books we talk about, as well as a link to the ALA award livestream so you can watch the awards in real time: https://www.literaticat.com/literaticast

Today James and Casey break down big words about weather, what it looks like to eat like an asshole, and how to set goals going into the new year. They also cover off the wall stuff like scuba diving, artesian water, and God only knows what else! . Follow us on Facebook and Insta: @Dirtyanddriven Email us: dirtyanddriven@gmail.com

All published abstracts can be found here AbstractsCategory 1: Amlodipine VasoplegiaAbstract 1: Vasodilation in patients with calcium channel blocker poisoning treated with high dose insulin: a comparison of amlodipine versus non-dihydropyridinesStudy of HDI on propranolol poisoned pigsStudy of Minnesota HDI protocolAbstract 2: Amlodipine anxiety: a 10-year review of amlodipine associated fatalitiesAbstract 3: Extracorporeal membrane oxygenation utilization for vasoplegic shock due to pediatric toxic ingestionsData of ECMO in poisoningCategory 2: XylazineAbstract 4: “Tranq dope” opioid overdose: clinical outcomes for emergency department patients with illicit opioid overdose adulterated with xylazineCategory 3: Case Reports with Terrifying Clinical ImplicationsAbstract 5: Recovery after poly-drug overdose despite blood flow imaging demonstrating no brain perfusionAbstract 6: Challenges in diagnosing an environmental cause of recurrent methemoglobinemiaAbstract 7: Acute thiamine deficiency as a complication of insulin euglycemic therapy for an amlodipine overdoseCategory 4: Comparative evidence, Prognostication, and TriageAbstract 8: Utility of pre four-hour iron concentration in predicting toxicologyAbstract 9: Andexanet alfa vs 4-factor prothrombin complex concentrate for intracranial hemorrhage at a level I trauma hospitalCategory 5: Rapid ReviewAbstract 10: Fentanyl and fentanyl analogue exposure among emergency personnel and first responders: a systematic reviewAbstract 11: Significance of falsely low creatinine values in diagnosing massive acetaminophen ingestionAbstract 12: Large dose intentional ciprofloxacin ingestion associated with false-positive urine immunoassay for oxycodone and fentanylAbstract 13: Don't make it a double?: a 20- year review of supratherapeutic amlodipine ingestions while on chronic therapyAbstract 14: Evaluation of pediatric lisdexamfetamine exposures reported to a statewide poison control systemAbstract 15: An assessment of the reliability of stated quantity in acute acetaminophen overdoses reported to a regional poison center

11/30/22 H1: Sam McCall leaving, RB Portal Prognostication & more! Learn more about your ad choices. Visit megaphone.fm/adchoices

We sit down with Dr. Jonathan Tward from the University of Utah to discuss his ASTRO 2022 plenary session results, the implications of AI driven prostate cancer prognostication for patients, and the future of prostate cancer care. Don't miss this awesome episode!@ASTRO_org@QuadShotNews@SamuelMarcromMD@LauraDoverMD@prostatemd@huntsmancancer@ACRORadOnc#radonc 

Looking forward to the future.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

To be considered "prolific" in the music world, an artist usually puts out an album every one or two years. But what about bands who routinely release several albums a year? On this week's Indiecast episode, hosts Steven Hyden and Ian Cohen deep dive into King Gizzard & The Lizard Wizard's wildly fruitful career (they've put out 23 albums since 2012, including five albums this year) (40:56). Plus, Indiecast shares their forecast for which bands will make the rounds on 2022 Albums Of The Year lists (20:56).In terms of music news this week, Taylor Swift's new album Midnights once again seemed to have the internet in a chokehold so Steven and Ian discuss how each Swift album cycle sparks the same debate about stans (3:32). Plus, Indiecast names bands they consider to be the Velvet Underground of this generation (10:16).This week's Recommendation Corner (54:09) has Ian telling listeners to check out Sam Prekop And John McEntire's recent album Sons Of, which is surprisingly melodic. Steven recommends Dazy, the project of Virginia-based singer-songwriter James Goodson, whose debut LP OUTOFBODY is fun, catchy, and bedroom pop-adjacent.New episodes of Indiecast drop every Friday. Listen to Episode 112 here or below and subscribe wherever you get your podcasts. You can submit questions for Steve and Ian at indiecastmailbag@gmail.com, and make sure to follow us on Instagram and Twitter for all the latest news. We also recently launched a visualizer for our favorite Indiecast moments. Check those out here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Open wide, here comes a “Hot N Ready” episode of AAO as right off the top we get a pizza breakdown from Harry, a man of means, who bewilderingly chooses to go with Little Caesar's. Brother Bri calls his shot with Thursday's “Race to Ten”. Tune in to see if the Celtics can get it done. Big stat of the day, when the spread is 6 points or fewer, teams are 73-0-2. So stick with the “Sal Special” of -9.5 on both sides. A “Russian Doll” of bets from the fellas emerges as everyone likes the Game, Half, and Quarter for their picks tonight. Cousin Sal likes Klay TPK likes Tatum for the “Picks of the Day” for your Underdog account, while Harry and Brother Bri like a few player props from Fan Duel Off to the PGA US Open as Writer/Author/Producer and friend of the show, Paul Koehorst stops in to talk about the PGA US Open and the lurking LIV league and gives his thoughts on how PGA can fix some issues. The challenges of Brookline, blind tee shots, and undulating greens, will be an issue for some but Paul thinks it looks promising for Justin Thomas. Is Scheffler on the slide? The fellas give their picks while Koehorst's literal diamond in the rough is Justin Thomas.   Harry has an NCAA World Series pick and it's the correct one, Hook Em Horns!